Ameriprise’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Ameriprise’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-107,198	Closed	-$895K	–	4054
2021 Q4	$895K	Buy	+107,198	New	+$883K	﹤0.01%	3307
2021 Q2	–	Sell	-12,000	Closed	-$123K	–	3993
2021 Q1	$123K	Buy	+12,000	New	+$131K	﹤0.01%	3754
2020 Q4	–	Sell	-12,824	Closed	-$104K	–	3847
2020 Q3	$104K	Buy	+12,824	New	+$79.5K	﹤0.01%	3636
2018 Q2	–	Sell	-177,500	Closed	-$3.97M	–	3720
2018 Q1	$3.97M	Sell	177,500 -3,566	-2%	-$79.1K	﹤0.01%	2338
2017 Q4	$2.31M	Sell	181,066 -3,177	-2%	-$46.7K	﹤0.01%	2585
2017 Q3	$2.87M	Buy	184,243 +57,335	+45%	+$811K	﹤0.01%	2426
2017 Q2	$1.78M	Sell	126,908 -34,566	-21%	-$740K	﹤0.01%	2665
2017 Q1	$3.55M	Buy	+161,474	New	+$3.42M	﹤0.01%	2277

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ameriprise's JNCE Position: Q1 2022 in Review

Ameriprise sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 107,198 shares — an estimated $895K sold.

Ameriprise first reported a position in JNCE in Q1 2017 and held it in 8 quarters. The position peaked at $3.97M in Q1 2018. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

Ameriprise reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Ameriprise sold 107,198 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $895K.
Ameriprise first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 8 quarters.
Ameriprise's Jounce Therapeutics, Inc. Common Stock position peaked at $3.97M in Q1 2018.
113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Ameriprise's 13F filing for Q1 2022, filed 16 May 2022.